Artiva Biotherapeutics develops allogeneic, off-the-shelf natural killer (NK) cell therapies, with lead candidate AlloNK designed to enhance antibody-dependent cellular cytotoxicity when combined with B-cell–targeted monoclonal antibodies. Programs focus on B-cell–driven autoimmune diseases such as rheumatoid arthritis and Sjögren’s disease, with earlier roots in scalable NK manufacturing technology. The model aims for cryopreserved, non–gene-edited cells that can be administered in outpatient or community settings.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -21.3 | — |
| Q3 2025 | 0 | — | -21.5 | — |
| Q4 2025 | 0 | — | -20.8 | — |
| Q1 2026 | 0 | — | -23.5 | — |
| Q2 2026 | 0 | — | -25 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: FTAI Infrastructure Inc. (FIP), Oak Valley Bancorp (OVLY), First United Corporation (FUNC), Lionheart Holdings (CUB), Commerce.com, Inc. (CMRC), SuperX AI Technology Limited (SUPX)